Eli Lilly & Co. (NYSE: LLY) announced the launch of 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide) for self-pay patients with obesity, priced at USD 499 under the new Zepbound Self Pay Journey Program.
Dosing Options
The program offers self-pay patients a range of Zepbound doses: 2.5 mg, 5 mg, 7.5 mg, and 10 mg. The 2.5 mg dose is priced at USD 349, while the 5 mg dose is available for USD 499 per month.
Pricing Adjustments
Eli Lilly has reduced the monthly prices for the 7.5 mg and 10 mg doses to USD 499 for the first fill and refills within 45 days of prior delivery, down from USD 599 and USD 699, respectively.-Fineline Info & Tech
